ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Sangamo Therapeutics, Inc. ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -6.97% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -142.43
2
The company has declared Negative results for the last 3 consecutive quarters
- NET SALES(9M) At USD 16.25 MM has Grown at -74.37%
- NET PROFIT(9M) At USD -90.66 MM has Grown at -95.05%
- RAW MATERIAL COST(Y) Grown by 44.75% (YoY)
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -75.61%, its profits have risen by 16.2%
4
Below par performance in long term as well as near term
- Along with generating -75.61% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Sangamo Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Sangamo Therapeutics, Inc.
-75.61%
-0.60
116.24%
S&P 500
20.78%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-25.91%
EBIT Growth (5y)
-6.97%
EBIT to Interest (avg)
-142.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.13
Sales to Capital Employed (avg)
3.12
Tax Ratio
0.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
35.51%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
19.11
EV to EBIT
-0.80
EV to EBITDA
-0.87
EV to Capital Employed
-3.65
EV to Sales
2.70
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1748.68%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at USD -55.18 MM
ROCE(HY)
Highest at 0%
-11What is not working for the Company
NET SALES(9M)
At USD 16.25 MM has Grown at -74.37%
NET PROFIT(9M)
At USD -90.66 MM has Grown at -95.05%
RAW MATERIAL COST(Y)
Grown by 44.75% (YoY
CASH AND EQV(HY)
Lowest at USD 48.53 MM
DEBT-EQUITY RATIO
(HY)
Highest at 43.55 %
Here's what is working for Sangamo Therapeutics, Inc.
Net Profit
Higher at USD -55.18 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Here's what is not working for Sangamo Therapeutics, Inc.
Net Sales
At USD 16.25 MM has Grown at -74.37%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Cash and Eqv
Lowest at USD 48.53 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at 43.55 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 44.75% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
